dipeptidyl
peptidas
iv
incretin
glucagonlik
degrad
enzym
contain
two
form
exert
variou
physiolog
function
particular
control
blood
glucos
action
diabet
use
inhibitor
block
attenu
degrad
prolong
action
sensit
insulin
activ
purpos
lower
blood
glucos
nonetheless
advers
effect
inhibitor
sever
hinder
clinic
applic
notabl
clinic
demand
novel
inhibitor
variou
sourc
includ
chemic
synthesi
herb
plant
fewer
side
effect
review
highlight
variou
strategi
name
comput
biolog
silico
vitro
enzymat
cell
assay
vivo
anim
test
seek
natur
inhibitor
botan
sourc
includ
herb
plant
pro
con
approach
new
inhibitor
candid
hit
discuss
accord
statist
intern
diabet
feder
idf
million
diabet
mellitu
dm
patient
worldwid
number
expect
increas
million
abnorm
high
blood
glucos
caus
insulin
insuffici
insensit
lead
sever
complic
chronic
renal
failur
microvascular
complic
cerebrovascular
accid
infarct
induc
high
glycat
serum
blood
vessel
protein
moreov
insuffici
insulin
signal
lead
decreas
glucos
uptak
blood
turn
result
ulcer
gangren
diabet
retinopathi
neuropathi
recent
dm
treatment
inclin
maintain
blood
glucos
level
within
normal
limit
eg
nutrit
therapi
physic
manag
medic
due
incur
natur
dm
diabet
medic
character
five
strategi
base
act
mechan
rais
insulin
secret
eg
sulfonylurea
meglitinid
analog
reduc
intestin
glucos
absorpt
eg
acarbos
trigger
insulinindepend
glucos
uptak
signal
eg
thiazolidinedion
biguanid
reduc
urin
glucos
reabsorpt
eg
gliflozin
prolong
insulin
sensit
eg
dipeptidyl
peptidas
inhibitor
glucagonlik
peptid
receptor
agonist
american
diabet
associ
antidiabet
drug
help
dm
patient
maintain
blood
glucos
level
variou
advers
effect
tabl
urinetract
infect
lactoacidosi
hypoglycemia
obes
drugrel
advers
effect
deterior
qualiti
life
dm
patient
creat
unsurmount
difficulti
proper
dose
regimen
clinic
set
observ
inhibitor
exert
similar
efficaci
reduc
blood
glucos
level
without
sever
advers
effect
hypoglycemia
compar
sulfonylurea
nevertheless
percept
natur
compound
dipeptidyl
peptidas
diabet
silico
vivo
variou
advers
side
effect
associ
current
inhibitor
still
observ
turn
sever
limit
practic
applic
clinic
demand
novel
inhibitor
variou
sourc
includ
chemic
synthesi
botan
sourc
contain
herb
plant
fewer
side
effect
articl
review
variou
approach
includ
silico
vitro
enzymat
cell
assay
vivo
anim
test
search
natur
inhibitor
treatment
type
diabet
two
form
kda
serin
proteas
contain
one
region
cytoplasm
region
amino
acid
coupl
transmembran
domain
amino
acid
extracellular
region
amino
acid
main
catalyt
domain
two
isoform
bodi
membranebound
compos
fulllength
peptid
solubl
whose
cytoplasm
transmembran
region
absent
form
exert
variou
biolog
activ
regul
physiolog
patholog
biolog
function
solubl
form
secret
lymphocyt
circul
blood
show
high
concentr
kidney
observ
play
variou
role
improv
skeleton
muscl
activ
immunocyt
activ
chemotaxi
homeostasi
secret
serum
via
respons
skelet
muscl
cell
upon
acut
physic
activ
feed
protein
hydrolys
secret
reduc
vasoconstrict
caus
neuropeptid
npi
subsequ
increas
arteriolar
diamet
skelet
muscl
provid
physiolog
explan
rais
train
effici
caus
addit
arteriolar
diamet
skelet
muscl
secret
act
myokin
stimul
inflamm
smooth
muscl
blood
vessel
activ
proteaseactiv
receptor
signal
pathway
increas
proinflammatori
cytokin
releas
final
stimul
smooth
muscl
cell
prolifer
tcell
activ
activ
tcell
prolifer
via
costimul
tcell
receptor
tcr
signal
tolllik
receptor
whose
activ
neither
associ
enzymat
activ
adenosin
deaminas
bind
hand
upregul
express
monocyt
signal
involv
monocyt
prolifer
noteworthi
tansi
et
al
prove
interact
transcript
regul
tat
marked
effect
viral
infect
prolifer
need
investig
attent
role
chemotaxi
regul
relat
degrad
chemokin
hematopoiet
stem
cell
home
attract
stromal
cellderiv
factor
colonystimul
factor
csf
substrat
accordingli
inhibit
improv
success
rate
transplant
analyz
relationship
activ
hematopoiet
stem
cell
transplant
known
solubl
membranebound
form
substrat
includ
numer
homeostat
hormon
npi
glucagon
peptid
secretin
accur
regul
blood
sugar
homeostasi
involv
insulin
sensit
secret
food
reward
appetit
ghrelin
leptin
cellular
metabol
adiponectin
activ
endstag
renal
diseas
patient
kidney
transplant
activ
found
decreas
kidney
transplant
result
suggest
serum
activ
potenti
biomark
monitor
progress
autoimmun
diseas
prognosi
organ
transplant
interestingli
serum
activ
associ
progress
chronic
obstruct
pulmonari
diseas
copd
highli
correl
respiratori
inflamm
obvious
indic
relationship
serum
activ
copd
progress
howev
prognosi
malign
pleural
mesothelioma
mpm
rare
pulmonari
malign
predict
activ
pleural
fluid
patholog
correl
activ
mpm
prognosi
still
veil
report
provid
interest
suggest
level
biomark
variou
diseas
easi
monitor
serum
bodi
fluid
remark
found
mainli
kidney
gastrointestin
tract
lymphocyt
reproduct
organ
biolog
activ
includ
regul
immun
respons
blood
vessel
function
also
name
tcell
costimul
tcell
receptor
respond
antigenpres
cell
thu
recent
journalssagepubcomhometaj
consid
potent
target
treatment
transplant
autoimmun
diseas
dolanbay
et
al
report
interest
studi
impact
inhibit
earli
pregnanc
import
treat
recurr
implant
failur
hematopoiet
stem
cell
transplant
graftversushost
diseas
gvhd
common
complic
critic
surviv
rate
transplant
zhang
et
al
prove
associ
cell
gvhd
cell
regul
inhibit
indic
current
inhibitor
help
amelior
onset
gvhd
impact
immun
regul
also
implic
autoimmun
diseas
hypersensit
express
level
cell
hashimoto
thyroid
patient
significantli
lower
healthi
subject
plausibl
attribut
diseas
progress
contrast
level
almost
higher
psoriat
skin
normal
skin
assert
involv
psoriat
develop
play
posit
role
asthma
progress
promot
tcell
activ
report
unequivoc
demonstr
posit
role
play
immun
regul
act
endotheli
epitheli
cell
regul
blood
vessel
function
addit
endotheli
inflamm
caus
role
endotheli
gener
involv
endotheli
migrat
angiogenesi
prolifer
hypoxia
statu
found
develop
endometriosi
xu
et
al
point
inhibitor
allevi
pulmonari
arteri
remodel
final
delay
develop
pulmonari
hypertens
regul
cardiovascular
function
inhibit
revers
diastol
left
ventricular
dysfunct
via
inhibit
relat
angiogenesi
involv
epithelialmesenchym
transit
emt
epitheli
cell
suggest
potenti
implic
promot
cancer
develop
fact
breast
cancer
metastasi
trigger
inhibit
pathway
howev
inhibitor
show
opposit
activ
nonsmal
cell
lung
cancer
suppress
cancer
cell
growth
via
macrophagemedi
natur
killer
nk
cell
activ
collect
studi
furnish
comprehens
descript
biolog
function
whole
bodi
manifest
inhibit
produc
unexpect
side
effect
endocrinolog
impact
promin
mediat
blood
glucos
inhibit
predomin
approach
treat
diabet
prolong
incretin
halfliv
within
serum
especi
type
dm
addit
suggest
sitagliptin
preserv
pancreat
function
subsequ
stabil
insulin
secret
shown
two
clinic
trial
sitagliptin
adopt
treat
slowli
progress
type
dm
sptiddm
latent
autoimmun
diabet
adult
lada
addit
clinic
treatment
level
use
biomark
instanc
high
serum
level
refer
elev
glycat
end
product
subsequ
evok
endotheli
cell
damag
diabet
nephropathi
incid
addit
high
serum
level
also
indic
wors
drug
respons
inhibitor
hyperglycemia
indic
poor
glycem
control
advanc
diseas
progress
inform
emphas
effect
inhibit
monitor
dm
treatment
method
screen
inhibitor
recent
known
natur
inhibitor
present
follow
silico
screen
inhibitor
virtual
screen
seamlessli
integr
drug
discoveri
develop
success
significantli
reli
compound
librari
especi
structur
divers
compound
librari
instanc
microalg
metabolit
screen
inhibitor
compar
synthes
chemic
natur
compound
librari
gener
consist
structur
divers
compound
synthet
counterpart
provid
better
screen
resourc
numer
studi
adopt
variou
natur
compound
librari
find
novel
inhibitor
list
tabl
uncommon
observ
dock
studi
carri
base
singl
crystal
structur
despit
fact
great
number
cocomplex
structur
deposit
protein
data
bank
pdb
deng
et
al
instanc
dock
seri
synthes
triazolebas
uracil
deriv
cocomplex
structur
pdb
code
use
standard
precis
sp
glide
inc
place
intern
gener
ligand
conform
variou
posit
orient
bind
pocket
deng
et
al
employ
gold
cambridg
crystallograph
data
center
genet
algorithm
ga
base
scheme
explor
conform
flexibl
ligand
rotat
flexibl
receptor
dock
synthes
pyrazolo
inhibitor
cocomplex
structur
pdb
code
note
glide
gold
flexibl
dock
algorithm
nevertheless
unrestrain
per
se
manifest
fact
consist
variou
bind
subsit
name
extens
etc
correspond
amino
acid
substrat
peptid
design
p
p
p
p
etc
nearest
farthest
cleavag
point
bind
shown
figur
compos
variou
hydrophob
residu
name
dyad
highli
plastic
furthermor
nabeno
et
al
categor
inhibitor
three
differ
class
figur
base
interact
inhibitor
subsit
list
tabl
observ
inhibitor
differ
class
bind
differ
subsit
tabl
natur
compound
librari
adopt
variou
studi
tradit
chines
medicin
databas
tcm
databas
taiwan
chen
natur
occur
plantbas
anticanc
compoundactivitytarget
databas
npact
mangal
et
al
natur
product
subset
zinc
databas
irwin
shoichet
et
al
bind
databas
bindingdb
liu
et
al
antidiabet
natur
compound
databas
adncd
khatoon
et
al
phenolexplor
rothwel
et
al
inhous
natur
product
databas
npd
zhang
et
al
nubb
databas
nubbedb
nguyen
et
al
turn
notic
promiscu
target
protein
promiscu
fulli
taken
account
unless
sophist
structurebas
ensembl
dock
scheme
svmposesvmscor
combinatori
ensembl
dock
analogbas
pharmacophor
ensembl
scheme
pharmacophor
ensemblesupport
vector
machin
adopt
argu
molecular
dynam
md
use
address
flexibl
illustr
studi
liu
et
al
nevertheless
lengthi
md
calcul
substanti
increas
comput
time
expens
make
impract
carri
highthroughput
fashion
let
alon
resourcedemand
quantum
mechan
qm
molecular
mechan
mm
algorithm
four
type
assay
method
screen
inhibitor
direct
test
direct
enzymat
assay
vitro
cell
assay
ex
vivo
assay
vivo
anim
test
test
compound
mix
direct
enzymat
assay
follow
ad
specif
substrat
peptid
glypropnitroanilid
chemic
pnitroanilid
releas
peptid
amount
determin
optic
absorpt
nm
noninhibit
state
method
fast
analysi
use
evalu
inhibit
pattern
calcul
k
valu
howev
minimum
chang
within
direct
enzymat
assay
directli
translat
actual
bioactiv
cell
anim
ex
vivo
assay
simul
biolog
interact
within
bodi
wherea
need
fresh
serum
tissu
sampl
sourc
moreov
previou
studi
report
mucos
inhibit
possibl
relat
onset
coeliac
diseas
autoimmun
disord
due
immun
respons
gluten
howev
modern
version
activ
assay
need
homogen
whole
intestin
biopsi
turn
lead
mucos
inhibit
yazbeck
et
al
deriv
new
substrat
c
isotop
releas
upon
reaction
requir
homogen
biopsi
complet
exoner
lead
higher
correl
compar
convent
counterpart
myocyt
pancreat
cell
often
use
cellbas
assay
discov
inhibitor
pancreat
islet
import
target
downstream
signal
pancreat
cell
indic
biomark
activ
addit
attenu
lipopolysaccharid
lp
induc
cardiomyocyt
inflamm
variat
inflammatori
signal
includ
erk
within
lpsinduc
cardiomyocyt
indirectli
gaug
activ
nevertheless
result
cellbas
assay
authent
repres
realist
situat
mainli
due
fact
consid
vivo
pharmacodynam
pharmacokinet
factor
nevertheless
direct
action
upon
target
cell
help
detail
intracellular
dynam
prior
clinic
anim
test
inhibitor
highlight
potenti
regimen
autoimmunediseas
base
characterist
tcell
activ
inflamm
notabl
autoimmun
anim
model
becom
platform
test
vivo
efficaci
inhibitor
longterm
administr
altern
vivo
assay
inhibitori
efficaci
verifi
diabet
anim
model
despit
fact
degrad
lead
insulin
desensit
secret
decreas
unvanquish
limit
vivo
test
endpoint
effect
observ
pretest
drug
candid
despit
fact
relat
clinic
situat
data
retriev
vitro
direct
enzymat
assay
synergist
essenti
understand
conceiv
hypoglycem
mechan
effect
studi
mainli
focus
immun
endocrin
neuron
system
end
earli
studi
report
incretin
molecular
target
suggest
implic
inhibitor
diabet
treatment
consequ
diabet
research
turn
new
paradigm
search
antidiabet
inhibitor
date
limit
natur
inhibitor
variou
sourcesorigin
report
tabl
natur
inhibitor
differ
origin
use
differ
approach
screen
compound
reach
target
summar
follow
addit
plant
sourc
inhibitor
anim
microb
singlesubclass
inhibitor
anim
microb
peptid
macrolid
respect
interestingli
predomin
subclass
inhibitor
terpenoid
peptid
phenol
flavonoid
protein
hydrolys
whey
barbel
yam
reduc
activ
enzymat
measur
partit
molecular
siev
highest
inhibit
peptid
sequenc
alapro
leuprovalprogln
trpsergli
pheserasp
found
nevertheless
result
vitro
enzymat
assay
guarante
promis
futur
sinc
physiolog
regul
far
complic
benchtop
experi
therefor
result
direct
enzymat
assay
new
candid
hit
requir
valid
vivo
investig
confirm
actual
therapeut
valu
compar
clinic
medicin
previou
section
describ
biolog
function
assay
method
known
natur
inhibitor
purport
treat
dm
howev
inhibit
possibl
caus
unexpect
sequela
owe
entangl
immun
respons
endotheli
function
fact
role
tumorigenesi
progress
respect
review
recent
lung
cancer
conclus
inhibitor
use
treat
dm
wherea
complic
immun
diseas
cancer
serious
consid
effect
virtual
screen
via
comput
biolog
informat
combin
vitro
enzymat
cell
assay
vivo
anim
test
offer
promis
approach
discov
candid
hit
expedit
preclin
develop
process
figur
nevertheless
poor
ill
drug
absorpt
distribut
metabol
excret
toxic
admetox
properti
make
substanti
contribut
drug
attrit
littl
effort
dedic
profil
admetox
properti
inhibitor
necessari
predict
adm
tox
paramet
process
virtual
screen
carri
adopt
scheme
consid
unstructur
natur
minim
latestag
failur
author
receiv
financi
support
research
authorship
andor
public
articl
